REGENXBIO Inc.
RGNX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RGNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company developing gene therapies for rare diseases, with a focus on MPS disorders and a strategic partnership to advance its pipeline.
Key risk: Capital need for operations
BioSniper Score
Based on 6 of 6 signals
Market Cap
$637.7M
Cash Runway
6.9 moLead Asset
ABBV-RGX-314 (Phase 3)
Next Catalyst
Phase3_Topline · Jun 1, 2028Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 10 clinical trials · 2 catalysts for REGENXBIO Inc..
REGENXBIO Inc. is a clinical-stage biotechnology company developing gene therapies for rare diseases, with a focus on MPS disorders and a strategic partnership to advance its pipeline.
- Ended 2024 with $244.9 million in cash, cash equivalents and marketable securities [sec · filed 2025-04-08].
- As of 2026-06-30, reported cash & equivalents of $38.5M, total revenue of $108.0M, net income of $22.7M, and shareholders' equity of $213.7M [sec].
- Achieved corporate objective of targeted cost reductions in excess of $50.0 million in 2024 stemming from a corporate restructuring plan [sec · filed 2025-04-08].
- Announced a strategic partnership with Nippon Shinyaku to develop and commercialize RGX-121 and RGX-111, with a $110.0 million upfront payment [sec · filed 2025-04-08].
What works
- Strategic partnership with Nippon Shinyaku provides $110.0 million upfront to support development of RGX-121 and RGX-111 [sec · filed 2025-04-08].
- Cost reduction initiatives exceeded $50.0 million in 2024, improving operational efficiency [sec · filed 2025-04-08].
- Positive net income of $22.7M as of 2026-06-30, indicating a period of profitability [sec].
What to weigh
- Cash & equivalents of $38.5M as of 2026-06-30 is relatively low, and the company expects to need significant additional capital to fund operations [sec_mda · as of 2026-08-06].
- The company faces numerous risks and uncertainties in the development and commercialization of gene therapy, including clinical trial delays and regulatory hurdles [sec_mda · as of 2026-08-06].
- Future capital requirements depend on many factors including clinical trial results and regulatory outcomes, creating financial uncertainty [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Cost reductions exceeded $50 million in 2024
“We achieved our corporate objective of targeted cost reductions in excess of $50.0 million in 2024 stemming from the corporate restructuring plan implemented in late 2023.”
SEC filings · April 8, 2025
Strategic partnership with Nippon Shinyaku for RGX-121 and RGX-111
“In the first quarter of 2025, the Company announced a strategic partnership with Nippon Shinyaku to develop and commercialize RGX-121 and RGX-111, with a $110.0 millio”
SEC filings · April 8, 2025
Need for significant additional capital
“As a result, we will need significant additional capital to fund our operations, which we may obtain through one or more equity offerings, debt financings or other third-party funding, including potential strategic alliances and licensing or collaboration arrangements.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2028-06-01 · Phase3_Topline — Phase 3 Topline: A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and — Topline data from a Phase 1/2/3 study of RGX-121 in MPS II will be read out, providing key efficacy and safety data.
- 2031-05-30 · Phase3_Topline — Phase 3 Topline: A Phase 3, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RGX 121 in Ped — Topline data from a Phase 3 study of RGX-121 in pediatric patients will be read out, informing the product's potential approval.
Risks & what to watch (3)›
Key risks
- Capital need for operations — The company will need significant additional capital to fund operations, which may require equity or debt financing [sec_mda · as of 2026-08-06].
- Clinical trial uncertainties — Future capital requirements depend on clinical trial enrollment, results, and potential delays or clinical holds [sec_mda · as of 2026-08-06].
- Regulatory and commercialization risks — Gene therapy development and commercialization involve numerous risks and uncertainties, including regulatory approval [sec_mda · as of 2026-08-06].
What to watch
- Progress of the strategic partnership with Nippon Shinyaku for RGX-121 and RGX-111, including any milestone payments [sec · filed 2025-04-08].
- Upcoming Phase 3 topline data for RGX-121 in MPS II expected around 2028-06-01 [upcoming catalysts].
- Upcoming Phase 3 topline data for RGX-121 in pediatric patients expected around 2031-05-30 [upcoming catalysts].
- Cash runway and any additional financing activities given the $38.5M cash position as of 2026-06-30 [sec].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run REGENXBIO Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available REGENXBIO Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
6.9 months
D/E 4.39 · 0% dilution
Lead: Phase 3
5 candidates
2 upcoming, next in ~641d
0 buys · 5 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
175
Total value held
$305.9M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 5,782,808 | $48.5M |
| vanguard capital management llc | 4,014,292 | $33.6M |
| state street corp | 2,731,485 | $22.9M |
| eversource wealth advisors, llc | 81,463 | $20.2M |
| morgan stanley | 2,066,157 | $17.3M |
| goldman sachs group inc | 1,839,463 | $15.4M |
| geode capital management, llc | 1,137,498 | $9.5M |
| aqr capital management llc | 1,051,712 | $8.8M |
| vanguard portfolio management llc | 1,018,901 | $8.5M |
| dimensional fund advisors lp | 1,010,381 | $8.5M |
Showing top 10 of 175 institutional holders of REGENXBIO Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 19, 2026- % of float
- 13.9%
- Days to cover
- 11.9
- Shares short
- 6,692,556
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RGNX short interestGovernance
Frequently asked questions
What is the AI investment thesis for REGENXBIO Inc.?
REGENXBIO Inc. is a clinical-stage biotechnology company developing gene therapies for rare diseases, with a focus on MPS disorders and a strategic partnership to advance its pipeline.
What is REGENXBIO Inc.'s lead drug candidate?
REGENXBIO Inc.'s most advanced tracked candidate is ABBV-RGX-314 (Phase 3) for Wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).
What is REGENXBIO Inc.'s next catalyst?
REGENXBIO Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and" — expected June 1, 2028.
Who is the CEO of REGENXBIO Inc.?
Mr. Curran M. Simpson M.S. is the chief executive officer of REGENXBIO Inc. (RGNX).
Where is REGENXBIO Inc. headquartered?
REGENXBIO Inc. (RGNX) is headquartered in Rockville, MD, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.